FILSPARI Demand Soars: Travere Posts 96% Sales Growth and Strong FSGS Launch
Travere stock jumps as FILSPARI sales surge, beating forecasts and showing strong patient demand and future growth potential.
/ 7 items
#TVTX↓
Travere Wins Full FDA Approval for FILSPARI – First-Ever Treatment for Rare Kidney Disease FSGS
FDA approved FILSPARI for FSGS kidney disease, showing it lowers protein in urine and slows damage. It offers a new treatment option for patients with few choices.
FDA Extends Review Timeline for Travere's FSGS Treatment
FDA delays approval decision for Filspari in rare kidney disease FSGS until April 2026. Travere Therapeutics (TVTX) continues commercial preparations for potential first FSGS treatment.
Travere Therapeutics Stock Plunges on FDA Approval Uncertainty
Travere Therapeutics shares drop 33% in premarket as FDA requests more data for FILSPARI FSGS approval, delaying potential first-ever treatment for rare kidney disease.
FDA Reaffirms Proteinuria Endpoint for FSGS: Positive Signal for Travere Therapeutics
FDA confirms proteinuria reduction as valid FSGS approval endpoint in Dimerix feedback, boosting confidence in Travere Therapeutics' upcoming Filspari decision.
Travere Therapeutics Surges After Swinging to Q3 Profit and Crushing Analyst Estimates
Travere Therapeutics shares jumped 15% after reporting a strong Q3 profit of $25.7M, driven by surging FILSPARI sales and better-than-expected earnings. Citi raised its price target to $48, citing optimism for FDA approval in early 2026.